General literature
New perspectives for better R&D performance: lessons learned from leading pharma companies

Schuhmacher A., Gassmann O., Knapp S., Hartl D., Hinder M.

Drug Discov Today 2026, 104677. Online ahead of print.

DOI
PubMed
Success examples
Computer-aided discovery of CDK16 inhibitors: a docking-augmented machine learning regression modelling approach

Alfararjeh T., Dauod S., Hatmal M., Adel A., Taha M. O.

J Comput Aided Mol Des. 2026, 40(1):93.

Aurora B inhibitor
DOI
PubMed
Success examples
Chronic pain in sickle cell disease: a role for lysophosphatidic acid

Viatchenko-Karpinski V., Khasabova I. A., Johns M., Neal L., Tang K., Golovko M. Y., Golovko A. M., Anjum S., Gupta K., Khasabov S. G., Simone D. A.

Blood 2026, ISSN 0006-4971. Online ahead of print.

Autotaxin (ATX) inhibitor
DOI
Success examples
Systematic drug profiling across BAF complex perturbations reveals distinct dependencies

Spang K., Barry C., Ntasiou C., Aretaki E., Wolf M., Schumbera E., Kielisch F., Bonn L., Welzel M., Rühle F., Schäfer C., Luck K., Schick S.

bioRxiv 2026, 03.11.710932. Online ahead of print.

Telomerase inhibitor
DOI
Success examples
IAP-based biodegraders can convert necroptosis to apoptosis and eliminate cancer driving protein complexes

Ma X., Vaillant F., Gopal D., Schoffer K., Shojaee F., Pang J., Baldwin C. A., Murphy J. M., Silke J., Tanzer M. C., Visvader J. E., Salvamoser R., Vince J. E.

Cell Chem Biol. 2026, 33(4):553-570.e5.

SMARCA2/4 PROTAC
DOI
PubMed
Success examples
Tumor metabolic adaptation induced by L-asparaginase reveals a vulnerability to PARP1/2 inhibitor in B-cell lymphomas

Aussel A., Nemazanyy I., Vandenberghe A., Meola P., Dorat N., Paul R., Habbouche L., Exposito L., Nottet N., Petrilli V., Chiche E., Mounier N., Marchetti S., Chaveroux C., Ricci J-E., Chiche J. 

Nat Commun 2026. 17(1):3305.

PHGDH Inhibitor PHGDH Inhibitor
DOI
PubMed